0001209191-21-028200.txt : 20210423
0001209191-21-028200.hdr.sgml : 20210423
20210423204931
ACCESSION NUMBER: 0001209191-21-028200
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210421
FILED AS OF DATE: 20210423
DATE AS OF CHANGE: 20210423
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spear Matthew A.
CENTRAL INDEX KEY: 0001766302
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 21851177
MAIL ADDRESS:
STREET 1: C/O POSEIDA THERAPEUTICS, INC.
STREET 2: 4242 CAMPUS POINT COURT, SUITE 700
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-21
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001766302
Spear Matthew A.
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2021-04-21
4
M
0
4000
1.322
A
15485
D
Common Stock
2021-04-21
4
S
0
4000
8.438
D
11485
D
Common Stock
2021-04-23
4
M
0
5000
1.322
A
16485
D
Stock Option (Right to Buy)
1.322
2021-04-21
4
M
0
4000
0.00
D
2026-06-19
Common Stock
4000
128861
D
Stock Option (Right to Buy)
1.322
2021-04-23
4
M
0
5000
0.00
D
2026-06-19
Common Stock
5000
123861
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.32 to $8.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
range set forth in this footnote.
The stock option is fully vested and exercisable.
/s/ Johanna Mylet, Attorney-in-Fact
2021-04-23